by | Jul 10, 2024 | Publications
Br J Haematol. 2024 Jul 9. doi: 10.1111/bjh.19633. Online ahead of print. NO ABSTRACT PMID:38981510 | DOI:10.1111/bjh.19633
by | Jul 9, 2024 | Publications
Blood Adv. 2024 Jul 9;8(13):3560-3561. doi: 10.1182/bloodadvances.2024013292. NO ABSTRACT PMID:38980672 | DOI:10.1182/bloodadvances.2024013292
by | Jul 9, 2024 | Publications
bioRxiv [Preprint]. 2024 Jun 30:2024.06.27.600975. doi: 10.1101/2024.06.27.600975. ABSTRACT Multiple Myeloma (MM) is a highly prevalent and incurable form of cancer that arises from malignant plasma cells, with over 35,000 new cases diagnosed annually in the United...
by | Jul 9, 2024 | Publications
Front Immunol. 2024 Jun 24;15:1383136. doi: 10.3389/fimmu.2024.1383136. eCollection 2024. ABSTRACT Multiple myeloma (MM) is a plasma cell disease with a preferential bone marrow (BM) tropism. Enforced expression of tissue-specific chemokine receptors has been shown to...
by | Jul 9, 2024 | Publications
Turk J Haematol. 2024 Jul 9. doi: 10.4274/tjh.galenos.2024.2024.0188. Online ahead of print. NO ABSTRACT PMID:38979562 | DOI:10.4274/tjh.galenos.2024.2024.0188
by | Jul 9, 2024 | Publications
Blood Cancer J. 2024 Jul 8;14(1):107. doi: 10.1038/s41408-024-01088-6. ABSTRACT The randomized, phase 2 GRIFFIN study (NCT02874742) evaluated daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM)....
